Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease-Reference-Cited by-同舟云学术

Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease

Published:2017-12 Issue: Volume:298 Page:236-245
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

West Andrew B.^ORCID

Funder

NIH

Michael J. Fox Foundation

American Parkinson's Disease Association

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference61 articles.

1. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine);Andres-Mateos;J. Neurosci.,2009

2. LRRK2 kinase inhibitors of different structural classes induce abnormal accumulation of lamellar bodies in type II pneumocytes in non-human primates but are reversible and without pulmonary functional consequences;Baptista,2015

3. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs;Baptista;PLoS One,2013

4. LRRK2 contributes to monocyte dysregulation in Parkinson's disease;Bliederhaeuser;Acta Neuropathol. Commun.,2016

5. Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury;Boddu;Hum. Mol. Genet.,2015

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Animal Models in Parkinson's Disease (PD): What Role They Play in Preclinical Translational Research;CNS & Neurological Disorders - Drug Targets;2024-02

2. Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM;Cell Discovery;2024-01-23

3. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson’s disease;Bioorganic Chemistry;2023-12

4. Exploring the interplay between metabolomics and genetics in Parkinson's disease: Insights from ongoing research and future avenues;Mechanisms of Ageing and Development;2023-12

5. Biomarkers in Parkinson’s disease: A state of the art review;Biomarkers in Neuropsychiatry;2023-12